GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » ROC (Joel Greenblatt) %

Arcadia Biosciences (Arcadia Biosciences) ROC (Joel Greenblatt) % : -627.96% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Arcadia Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -627.96%.

The historical rank and industry rank for Arcadia Biosciences's ROC (Joel Greenblatt) % or its related term are showing as below:

RKDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3881.84   Med: -1638.08   Max: -83.03
Current: -481.06

During the past 12 years, Arcadia Biosciences's highest ROC (Joel Greenblatt) % was -83.03%. The lowest was -3881.84%. And the median was -1638.08%.

RKDA's ROC (Joel Greenblatt) % is ranked worse than
97.3% of 1888 companies
in the Consumer Packaged Goods industry
Industry Median: 11.93 vs RKDA: -481.06

Arcadia Biosciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 33.70% per year.


Arcadia Biosciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Arcadia Biosciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences ROC (Joel Greenblatt) % Chart

Arcadia Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,388.79 -83.03 -301.94 -249.80 -473.94

Arcadia Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -417.46 -431.47 -392.05 -550.76 -627.96

Competitive Comparison of Arcadia Biosciences's ROC (Joel Greenblatt) %

For the Packaged Foods subindustry, Arcadia Biosciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcadia Biosciences's ROC (Joel Greenblatt) % Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's ROC (Joel Greenblatt) % falls into.



Arcadia Biosciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.514 + 1.958 + 0.858) - (2.468 + 0 + 0.27)
=0.592

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.76 + 1.831 + 0.55) - (1.807 + 0 + 0.27)
=1.064

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Arcadia Biosciences for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.104/( ( (1.176 + max(0.592, 0)) + (1.023 + max(1.064, 0)) )/ 2 )
=-12.104/( ( 1.768 + 2.087 )/ 2 )
=-12.104/1.9275
=-627.96 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcadia Biosciences  (NAS:RKDA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Arcadia Biosciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcadia Biosciences (Arcadia Biosciences) Business Description

Traded in Other Exchanges
Address
5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a producer and marketer of innovative, plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements primarily in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.
Executives
Thomas J. Schaefer officer: Chief Financial Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot officer: Chief Executive Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley officer: Chief Financial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik officer: Chief Marketing Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier officer: Chief Growth Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella director 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan officer: Chief Financial Officer C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz officer: Chief Technology Officer 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter officer: Chief Commercial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray director 228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey director, officer: President and CEO ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu officer: VP Product Development ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder director C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328